Pharmacophore Modelling and Virtual Screening for Identification of New Aurora‐A Kinase Inhibitors

Aurora‐A has been identified as one of the most attractive targets for cancer therapy and a considerable number of Aurora‐A inhibitors have been reported recently. In order to clarify the essential structure–activity relationship for the known Aurora‐A inhibitors as well as identify new lead compounds against Aurora‐A, 3D pharmacophore models were developed based on the known inhibitors. The best hypothesis, Hypo1, was used to screen molecular structural databases, including Specs and China Natural Products Database for potential lead compounds. The hit compounds were subsequently subjected to filtering by Lipinski’s rules and docking study to refine the retrieved hits and as a result to reduce the rate of false positive. Finally, 39 compounds were purchased for further in vitro assay against several human tumour cell lines including A549, MCF‐7, HepG2 and PC‐3, in which Aurora‐A is overexpressed. Two compounds show very low micromolar inhibition potency against some of these tumour cells. And they have been selected for further investigation.

[1]  Qian Huang,et al.  The Discovery of Novel Vascular Endothelial Growth Factor Receptor Tyrosine Kinases Inhibitors: Pharmacophore Modeling, Virtual Screening and Docking Studies , 2007, Chemical biology & drug design.

[2]  P. Vianello.  Aminopyridines: selective AuroraA inhibitors , 2007 .

[3]  Paola Storici,et al.  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. , 2006, Journal of medicinal chemistry.

[4]  C. Deng,et al.  Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation , 2006, Oncogene.

[5]  J. Ruderman,et al.  Aurora A, Meiosis and Mitosis , 2004, Biology of the cell.

[6]  H. Koblish,et al.  The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[7]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[8]  D. V. Von Hoff,et al.  Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach , 2006, Molecular Cancer Therapeutics.

[9]  S. Vadivelan,et al.  Virtual Screening Studies to Design Potent CDK2‐Cyclin A Inhibitors. , 2007 .

[10]  A. Vulpetti,et al.  Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. , 2005, Journal of medicinal chemistry.

[11]  S. Weiss,et al.  A STUDY OF THE CARDIOVASCULAR RESPONSES IN MAN TO THE INTRAVENOUS AND INTRA-ARTERIAL INJECTION OF ACETYLCHOLINE , 1932 .

[12]  D. McRee,et al.  Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors. , 2006, Bioorganic & medicinal chemistry letters.

[13]  D. Townsend,et al.  Evaluation of Lipophilins as Determinants of Tumor Cell Response to Estramustine , 2005, Journal of Pharmacology and Experimental Therapeutics.

[14]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[15]  Domenico Coppola,et al.  Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  Kyung S. Lee,et al.  Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026. , 2003, Cancer research.

[17]  D. Mahadevan,et al.  Aurora kinase targeted therapeutics in oncology: past, present and future , 2007, Expert opinion on drug discovery.

[18]  P. Workman,et al.  Hit generation and exploration: imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases. , 2007, Bioorganic & medicinal chemistry letters.

[19]  Qian Huang,et al.  Pharmacophore modeling and in silico screening for new KDR kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[20]  P. Kussie,et al.  Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases. , 2005, Bioorganic & medicinal chemistry letters.

[21]  Stephen S. Taylor,et al.  Aurora-kinase inhibitors as anticancer agents , 2004, Nature Reviews Cancer.

[22]  H. Katayama,et al.  Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. , 1998, Cancer research.

[23]  G. Schwartz,et al.  Aurora Kinases: New Targets for Cancer Therapy , 2006, Clinical Cancer Research.

[24]  A. Ullrich,et al.  Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling. , 2005, Cancer research.

[25]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[26]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[27]  Mathias Schmidt,et al.  Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[28]  H. Friess,et al.  Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.